Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Sud, Sachin
and
Cuthbertson, Brian H.
2011.
Understanding health economic analysis in critical care.
Current Opinion in Critical Care,
Vol. 17,
Issue. 5,
p.
504.
Jobanputra, P.
2011.
A clinician's critique of rheumatoid arthritis health economic models.
Rheumatology,
Vol. 50,
Issue. suppl 4,
p.
iv48.
Garattini, Livio
and
Padula, Anna
2011.
To model or not to model: lessons from two vaccinations.
The European Journal of Health Economics,
Vol. 12,
Issue. 3,
p.
189.
Schaaber, Jörg
Kochen, Michael M.
Müller-Oerlinghausen, Bruno
and
Niebling, Wilhelm
2011.
Interessenkonflikte in der Medizin.
p.
237.
Schott, Gisela
Lieb, Klaus
and
Ludwig, Wolf-Dieter
2011.
Interessenkonflikte in der Medizin.
p.
265.
Burls, Amanda
and
Sandercock, Josie
2011.
Decision‐making under conditions of uncertainty–what can we learn from palivizumab?.
Acta Paediatrica,
Vol. 100,
Issue. 10,
p.
1302.
Hui, David
Reddy, Akhila
Parsons, Henrique A.
and
Bruera, Eduardo
2012.
Reporting of Funding Sources and Conflict of Interest in the Supportive and Palliative Oncology Literature.
Journal of Pain and Symptom Management,
Vol. 44,
Issue. 3,
p.
421.
Arana, Estanislao
and
Catalá-López, Ferrán
2012.
Cost–effectiveness of iodinated contrast media for CT scanning in Spain: a decision-based analysis.
Imaging in Medicine,
Vol. 4,
Issue. 2,
p.
193.
Slørdal, Lars
Eggen, Anne
and
Rygnestad, Tarjei
2012.
Interessekonflikter - en kunnskapsbasert tilnærming.
Tidsskrift for Den norske legeforening,
Vol. 132,
Issue. 11,
p.
1358.
Hill, Suzanne R
2012.
Cost-effectiveness analysis for clinicians.
BMC Medicine,
Vol. 10,
Issue. 1,
Krimsky, Sheldon
2013.
Do Financial Conflicts of Interest Bias Research?.
Science, Technology, & Human Values,
Vol. 38,
Issue. 4,
p.
566.
Catalá-López, Ferrán
Sanfélix-Gimeno, Gabriel
Ridao, Manuel
Peiró, Salvador
and
Keyhani, Salomeh
2013.
When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins.
PLoS ONE,
Vol. 8,
Issue. 7,
p.
e69462.
Husereau, Don
Drummond, Michael
Petrou, Stavros
Carswell, Chris
Moher, David
Greenberg, Dan
Augustovski, Federico
Briggs, Andrew H.
Mauskopf, Josephine
and
Loder, Elizabeth
2013.
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Value in Health,
Vol. 16,
Issue. 2,
p.
231.
Thorn, Joanna C.
Noble, Sian M.
and
Hollingworth, William
2013.
Timely and Complete Publication of Economic Evaluations Alongside Randomized Controlled Trials.
PharmacoEconomics,
Vol. 31,
Issue. 1,
p.
77.
Yang, Mo
Patil, Dhaval S
Tufail, Waqas
and
Issa, Amalia M
2013.
The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence.
Expert Review of Pharmacoeconomics & Outcomes Research,
Vol. 13,
Issue. 5,
p.
597.
Afzali, Hossein Haji Ali
Karnon, Jonathan
and
Merlin, Tracy
2013.
Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions.
Medical Decision Making,
Vol. 33,
Issue. 3,
p.
325.
John-Baptiste, Ava A.
Wu, Wei
Rochon, Paula
Anderson, Geoffrey M.
Bell, Chaim M.
and
Miller, Todd W.
2013.
A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer.
PLoS ONE,
Vol. 8,
Issue. 5,
p.
e62614.
Darst, Marc A.
Reddan, Jennifer
and
Feneran, Ashley N.
2013.
Comprehensive Dermatologic Drug Therapy.
p.
757.
van de Vooren, Katelijne
Duranti, Silvy
Curto, Alessandro
and
Garattini, Livio
2014.
A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries.
Applied Health Economics and Health Policy,
Vol. 12,
Issue. 1,
p.
33.
Chambers, James D.
Thorat, Teja
Pyo, Junhee
Chenoweth, Matthew
and
Neumann, Peter J.
2014.
Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs.
Health Affairs,
Vol. 33,
Issue. 10,
p.
1751.